Generic Name and Formulations:
Cetrorelix (as acetate) 0.25mg, 3mg; per vial; pwd for SC inj after reconstitution.
EMD Serono, Inc.
Indications for CETROTIDE:
Inhibition of premature LH surges in women undergoing controlled ovarian stimulation for in vitro fertilization.
Give by SC inj into lower abdominal wall during early to mid-follicular phase; see literature. 3mg once on stimulation day 7, or 0.25mg daily beginning on stimulation day 5 or 6 and continuing until day of hCG administration.
Pregnancy (Cat.X). Nursing mothers.
Do complete gynecological and endocrinological exam first.
Ovarian hyperstimulation syndrome, nausea, headache, inj site reactions, elevated enzymes (eg, ALT, alkaline phosphatase).
Vials 0.25mg (w. diluent)—1
3mg (w. diluent)—1
Endocrinology Advisor Articles
- FDA Approves Admelog Short-Acting Insulin Lispro Injection
- Fertility Hormone Therapy and Cardiovascular Outcomes: What We Know
- Effects of Peer Influence in Adolescents With Type 1 Diabetes
- More Evidence That Saxagliptin Does Not Increase Risk for AMI in Diabetes
- One-Hour Glucose Readings Predict T2D Risk Better Than 2-Hour Measurements
- FDA: Vitamin B7 May Interfere With Lab Tests for Hormone Levels
- Injected and Oral Medications Equally Safe for Gestational Diabetes
- Adjunctive Dapagliflozin Improves Glycemic Control in T1D
- Estradiol Therapy May Benefit Overall Cognition in Postmenopausal Women
- Stopping Postmenopausal HT May Increase Risk for Cardiac, Stroke Death
- Psychosocial Benefits of a Bihormonal Bionic Pancreas System in T1D
- Safety of Chronic Total Occlusion Percutaneous Coronary Intervention in Diabetes
- Oral Insulin Not a Reliable Preventive Strategy for Type 1 Diabetes
- Prevention of Bone Mineral Density Loss Needed in Epilepsy
- Gastric Bypass Blunts B-Cell Sensitivity During Glycemia